Invenirex, a Newcastle-based biotech company specializing in PCR laboratory tests, has appointed Alastair Carrington as Non-Executive Chairman. Carrington, who brings extensive experience in commercial strategy and leadership in deep tech, will guide the company’s roll-out of an AI diagnostic platform. The appointment is viewed as a strategic move to further disrupt the market for PCR laboratory tests. DSW Ventures is the Private Equity firm backing Invenirex.
Biotechnology, Artificial Intelligence, Private Equity,United Kingdom
Invenirex appoints Chair to help guide roll-out of AI diagnostic platform